Antisense News and Research

RSS
Antisense is the non-coding strand in double-stranded DNA. The antisense strand serves as the template for mRNA synthesis.
Kylin Therapeutics receives notice of allowance for its first U.S. patent application

Kylin Therapeutics receives notice of allowance for its first U.S. patent application

OncoGenex' OGX-011 receives additional FDA Fast Track Designation for treating metastatic prostate cancer

OncoGenex' OGX-011 receives additional FDA Fast Track Designation for treating metastatic prostate cancer

AVI BioPharma receives $11.5M DTRA fund to develop AVI-7012 for treating Junin virus infection

AVI BioPharma receives $11.5M DTRA fund to develop AVI-7012 for treating Junin virus infection

iCo Therapeutics, CPDD sign collaboration development agreement

iCo Therapeutics, CPDD sign collaboration development agreement

Bio-Path Holdings to develop liposome tumor targeting technology

Bio-Path Holdings to develop liposome tumor targeting technology

JPO to grant patent from the Tuschl III patent series

JPO to grant patent from the Tuschl III patent series

Santaris Pharma establishes its operations in the U.S.

Santaris Pharma establishes its operations in the U.S.

Altair announces positive Phase I results for AIR645 in treating asthma

Altair announces positive Phase I results for AIR645 in treating asthma

Zabecor Pharmaceuticals initiates Phase II clinical trial of its Excellair asthma drug

Zabecor Pharmaceuticals initiates Phase II clinical trial of its Excellair asthma drug

Trabedersen granted orphan drug designation from both FDA And EMEA for treating pancreatic carcinoma

Trabedersen granted orphan drug designation from both FDA And EMEA for treating pancreatic carcinoma

USPTO allows Isis an additional patent for single-stranded RNAi technology

USPTO allows Isis an additional patent for single-stranded RNAi technology

EPO issues grant for a patent in Kreutzer-Limmer III patent series

EPO issues grant for a patent in Kreutzer-Limmer III patent series

Teva Pharmaceutical Industries to present MS treatment research data

Teva Pharmaceutical Industries to present MS treatment research data

GS-101 effective in inhibiting and regressing corneal neovascularisation

GS-101 effective in inhibiting and regressing corneal neovascularisation

Phase II result reveals effectiveness of GS-101 eye drops at inhibiting corneal neovascularisation

Phase II result reveals effectiveness of GS-101 eye drops at inhibiting corneal neovascularisation

AVI BioPharma's peptide-conjugated PMO chemistry to be discussed at two upcoming scientific meetings

AVI BioPharma's peptide-conjugated PMO chemistry to be discussed at two upcoming scientific meetings

Study suggests that connective tissue growth factor plays a vital role in liver fibrosis progression

Study suggests that connective tissue growth factor plays a vital role in liver fibrosis progression

Shire collaborates with Santaris Pharma to develop Locked Nucleic Acid technology

Shire collaborates with Santaris Pharma to develop Locked Nucleic Acid technology

Santaris Pharma to discover and develop new RNA-based medicines for treating rare genetic disorders

Santaris Pharma to discover and develop new RNA-based medicines for treating rare genetic disorders

Cut back in research and development expenses helps to decrease losses in second quarter for Ico Therapeutics

Cut back in research and development expenses helps to decrease losses in second quarter for Ico Therapeutics